Takagi Seiji, Mandai Michiko, Hirami Yasuhiko, Sugita Sunao, Takahashi Masayo, Kurimoto Yasuo
Department of Ophthalmology, Kobe City Eye Hospital, 2-1-8, Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan.
Department of Ophthalmology, Kobe City Medical Center General Hospital, 2-2 Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan.
Jpn J Ophthalmol. 2018 Sep;62(5):568-575. doi: 10.1007/s10384-018-0611-8. Epub 2018 Jul 12.
Stem cell therapy is a potential treatment for retinal disorders. We are currently exploring treating HLA matched patients of age-related macular degeneration (AMD) by using allogenic retinal pigment epithelium cells derived from induced pluripotent stem cells (iPS-RPE) from human leukocyte antigen (HLA) homozygote donors. The purpose of this study was to investigate the frequency of HLA class I and II alleles and haplotypes in Japanese patients with AMD.
Cross-sectional observation clinical study.
A total of 138 consecutive patients diagnosed with neovascular AMD (mean age, 76.0 ± 7.8 years, 105 men) and 300 controls were included in the study. The frequencies of HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 alleles were determined using illumina MiSeq platform. Frequencies of HLA alleles at six loci in patients with AMD were compared with those of the controls.
The alleles with the highest prevalence at each locus were A24:02 (29.7%), B52:01 (15.5%), C12:02 (16.1%), DRB109:01 (19.1%), DQB106:01 (23.2%), and DPB1 05:01 (40.5%). There were no significant associations between the HLA alleles and AMD. The most common haplotype was A24:02-B52:01-C12:02-DRB115:02-DQB106:01-DPB109:01, with a 9.8% genetic frequency among all haplotypes, detected in 18.8% of the patients.
The genotype of HLA in patients with AMD was not different from that in the Japanese control population. Thus, therapy with iPS-RPEof the most frequent HLA haplotype could be a feasible alternative for AMD in a wider population.
干细胞疗法是视网膜疾病的一种潜在治疗方法。我们目前正在探索通过使用来自人类白细胞抗原(HLA)纯合子供体的诱导多能干细胞(iPS-RPE)衍生的同种异体视网膜色素上皮细胞来治疗年龄相关性黄斑变性(AMD)的HLA匹配患者。本研究的目的是调查日本AMD患者中HLA I类和II类等位基因及单倍型的频率。
横断面观察性临床研究。
本研究共纳入138例连续诊断为新生血管性AMD的患者(平均年龄76.0±7.8岁,男性105例)和300例对照。使用Illumina MiSeq平台确定HLA-A、-B、-C、-DRB1、-DQB1和-DPB1等位基因的频率。将AMD患者六个位点的HLA等位基因频率与对照组进行比较。
每个位点患病率最高的等位基因分别为A24:02(29.7%)、B52:01(15.5%)、C12:02(16.1%)、DRB109:01(19.1%)、DQB106:01(23.2%)和DPB105:01(40.5%)。HLA等位基因与AMD之间无显著关联。最常见的单倍型是A24:02-B52:01-C12:02-DRB115:02-DQB106:01-DPB109:01,在所有单倍型中的基因频率为9.8%,在18.8%的患者中检测到。
AMD患者的HLA基因型与日本对照人群无差异。因此,使用最常见HLA单倍型的iPS-RPE进行治疗可能是更广泛人群中AMD的一种可行替代方案。